Stoke Therapeutics Reports Positive Long-Term Data for Zorevunersen, Aims for 2027 FDA Submission
Event summary
- Stoke Therapeutics reported 4-year data from open-label extension studies showing durable reductions in seizures and improvements in cognition and behavior for zorevunersen in Dravet syndrome patients.
- The Phase 3 EMPEROR study is on track to complete enrollment in June 2026, with a data readout expected in mid-2027 to support a rolling NDA submission to the FDA.
- Stoke dosed the first patient in the Phase 1 OSPREY study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in February 2026.
- The company reported $411.0 million in cash and marketable securities as of March 31, 2026, expected to fund operations into 2028.
The big picture
Stoke Therapeutics is advancing its lead candidate, zorevunersen, through critical late-stage trials with the aim of becoming the first to offer a disease-modifying treatment for Dravet syndrome. The company's financial position remains strong, supporting its operational runway through a potential U.S. launch. The broader biotech sector is watching closely as RNA medicine continues to gain traction in addressing rare genetic disorders.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 EMPEROR study results will support a successful rolling NDA submission and potential approval of zorevunersen in early 2028.
- Pipeline Progress
- The pace at which STK-002 advances through Phase 1 trials and the potential for Stoke to identify a clinical candidate for SYNGAP1 treatment in 2026.
- Commercial Readiness
- How Stoke prepares for the potential U.S. launch of zorevunersen while managing increasing personnel and launch readiness expenses.
Related topics